Aziende Chimiche Riunite Angelini Francesco S.p.A — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications2liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
BLESS — Cenobamate in Adults With Focal-Onset SeizuresThe BLESS Study contributes to filling this information gap by collecting data from the Italian clinical practice and the Compassionate Use Program, to better characterize the clinical profile of cenobamate describing its effectiveness, safety and tolerability in adult patients diagnosed with uncontrolled focal epilepsy despite the use of at least two antiepileptic medicinal products.	Épilepsie	À vérifier	À vérifier	Italy	À vérifier
BLESS — Cenobamate in Adults With Focal-Onset SeizuresThe BLESS Study contributes to filling this information gap by collecting data from the Italian clinical practice and the Compassionate Use Program, to better characterize the clinical profile of cenobamate describing its effectiveness, safety and tolerability in adult patients diagnosed with uncontrolled focal epilepsy despite the use of at least two antiepileptic medicinal products.	Épilepsie	À vérifier	À vérifier	Italy	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
BLESS — Cenobamate in Adults With Focal-Onset Seizures	Épilepsie	À vérifier	NCT05859854	BLESS — Cenobamate in Adults With Focal-Onset Seizures	ACTIVE_NOT_RECRUITING

Publications

2

Molécule	Indication / population	Titre	Journal	Date
BLESS — Cenobamate in Adults With Focal-Onset Seizures		Effectiveness and Safety of Adjunctive Cenobamate in People with Focal-Onset Epilepsy: Evidence from the First Interim Analysis of the BLESS Study.	Neurology and therapy
BLESS — Cenobamate in Adults With Focal-Onset Seizures		Effectiveness and safety of adjunctive cenobamate in people with focal-onset epilepsy: Interim results after 24-week observational period from the BLESS study.	Epilepsia